AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04148534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocroniom, Non Depolarizing Muscle Relaxant
Description: compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
Study NCT04148534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocroniom, Non Depolarizing Muscle Relaxant
Description: compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
Study NCT03056677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: 200mls water will be given prior to a mixed carbohydrate meal
Study NCT03056677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal Whey protein
Description: Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
Study NCT03056677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified whey protein
Description: Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
Study NCT03049761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water Flosser
Description: Power interdental cleaner
Study NCT03049761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: String Floss
Description: Mechanical interdental cleaner
Study NCT03049761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: ADA standard soft bristle toothbrush
Study NCT02792231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab subcutaneous injection
Description: Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study NCT02792231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide-matching placebo capsules
Description: Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
Study NCT02792231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide capsule
Description: Teriflunomide 14 mg oral capsule taken once daily
Study NCT02792231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo of ofatumumab subcutaneous injections
Description: Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study NCT01572103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Administration of 4 cups of coffee per day for 1 month
Study NCT01572103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: coffee abstinence
Description: total abstinence for both coffee and caffeine containing beverages
Study NCT02567747 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data will be collected retrospectively for cases identified through RIPS\*/ DANE\*\* from 2008 until 2014 and through PAI\*\*\* from 2009 until 2014. \*Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. \*\*Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. \*\*\*Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
Study NCT02107183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow (Fisher & Paykel Healthcare)
Description: This device delivers high-flow oxygen through nasal cannula
Study NCT02107183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Description: This device delivers low-flow oxygen at predetermined concentrations
Study NCT01593332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: two 500 mg rituximab infusions 2 weeks apart
Study NCT01593332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 500mg,two times with two weeks interval
Study NCT04073186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS with Transitions™
Description: JJVC Marketed Contact Lens
Study NCT02461667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP plus Placebo Gel
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study NCT02461667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus Alendronate gel
Description: Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
Study NCT02461667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus Metformin gel
Description: Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
Study NCT02987751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine + Glulisine
Description: Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
Study NCT02987751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed analogue insulin (70/30)
Description: Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
Study NCT03617952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3 Bio Intervention
Description: Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
Study NCT04343872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Receive lifestyle modification alone
Description: Participants will receive a 12-month lifestyle intervention program (telehealth + peer coach). The intervention comprises of the Center for Disease Control and Prevention (CDC)-adapted DPP Prevent Type 2 (PreventT2) lifestyle intervention program consisting of 26 classes delivered by trained health educators via telehealth. Additionally, the peer coach provides ongoing support over 12-months with tapered calls mirroring ongoing classes. Participants are randomized at the practice level. Two clinics will be randomized to receive the lifestyle intervention program alone.
Study NCT04343872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receive lifestyle modification alone
Description: Participants will receive a 12-month lifestyle intervention program (telehealth + peer coach). The intervention comprises of the Center for Disease Control and Prevention (CDC)-adapted DPP Prevent Type 2 (PreventT2) lifestyle intervention program consisting of 26 classes delivered by trained health educators via telehealth. Additionally, the peer coach provides ongoing support over 12-months with tapered calls mirroring ongoing classes. Participants are randomized at the practice level. Two clinics will be randomized to receive the lifestyle intervention program alone.
Study NCT03011281 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Study NCT00992758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iodine-131 Anti-B1 Antibody
Description: Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached.
Study NCT04019353 — intervention group
Intervention type: GENETIC
Intervention: cf-DNA Collection
Description: For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations.
Study NCT05757648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-buffered Anesthetic
Description: non-buffered LA, 2% lidocaine with epinephrine 1:100,000
Study NCT05757648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Anesthetic
Description: A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.
Study NCT05757648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onset
Description: The test solution will be made by a mixing pen called Onset- This mixing pen Onset will deliver 0.18 mL of sodium bicarbonate solution into the anesthetic cartridge.
Study NCT03987477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation bias modification program
Description: Brief online program aimed at the modification of negative interpretation biases.
Study NCT03987477 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list
Description: Waiting list procedure for the control group.
Study NCT02163824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 0.25%
Description: KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study NCT02163824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 1.0%
Description: KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study NCT02163824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of KPI-121 0.25%
Description: Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study NCT02163824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of KPI-121 1.0%
Description: Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study NCT02249936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722
Study NCT02249936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT03915171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next generation sequencing
Description: NGS can provide genetic and MSI test for patients
Study NCT02581306 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise session
Description: There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
Study NCT02982902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV specific adoptive t-cells
Description: It is expected that the cell dose will be in the range of 10\^3 - 10\^5 virus - specific, antigen selected T cells per kg of recipient weight.
Study NCT00619515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
Study NCT00619515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implanted fiducial-based imaging
Description: Undergo fiducial placement imaging
Study NCT00619515 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
Study NCT04343872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Description: The two other clinics will be randomized to receive the lifestyle intervention program (described above) with METFORMIN therapy recommendations. Participants are randomized at the practice level. The primary care provider at the clinic will prescribe metformin and participants would be encouraged to take it if the primary care provider consider prescribing.
Study NCT01850446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: Safety and Efficacy
Study NCT01850446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Safety and Efficacy
Study NCT02295553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02295553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT03820674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Conservation plus Problem Solving Therapy
Description: EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.
Study NCT03820674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Intervention
Description: The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
Study NCT03725085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex™ extended-release (SE)
Description: 2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
Study NCT01934257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Marketed milk-based lactose-containing infant formula
Study NCT01934257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Marketed milk-based lactose-free infant formula
Study NCT01934257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Marketed soy-based lactose-free infant formula
Study NCT00327106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (Exacyl)
Description: 15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
Study NCT00327106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
Study NCT00724178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol plus calcium carbonate
Description: oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
Study NCT00724178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol plus calcium carbonate
Description: oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
Study NCT02408133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
Study NCT00925262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
Study NCT00925262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
Study NCT00925262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nonspecific counseling
Description: nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
Study NCT02102789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
Study NCT02102789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI
Description: Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
Study NCT01485094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6010
Description: Oral solution given once daily.
Study NCT01485094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
Study NCT01485094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily.
Study NCT00836589 — intervention group
Intervention type: DEVICE
Intervention: ICD Therapy - ICD Lead Registry
Description: Collecting long-term safety and efficacy data on a family of market-released ICD leads.
Study NCT02997943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1 Treatment: APP
Description: Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.
Study NCT02997943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1 Treatment: APP + Coaching
Description: Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.
Study NCT02997943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2 Treatment Strategy: Modest Step-up
Description: In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
Study NCT02506712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartDrive assisting device
Description: oxygen consumption
Study NCT02997943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2 Treatment Strategy: Vigorous Step-up
Description: In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
Study NCT02506712 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SmartDrive assisting device
Description: oxygen consumption
Study NCT02506712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard manuel wheelchair
Description: oxygen consumption
Study NCT02506712 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard manuel wheelchair
Description: oxygen consumption
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.03 mg
Description: A single dose of CC-220 0.03 mg will be administered orally once a day.
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.1 mg
Description: A single dose of CC-220 0.1 mg will be administered orally once a day.
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.3 mg
Description: A single dose of CC-220 0.3 mg will be administered orally once a day.